Evidence map›Paper›PMID 26221037›Full record

ArticleThe Journal of biological chemistry2015

Pli1(PIAS1) SUMO ligase protected by the nuclear pore-associated SUMO protease Ulp1SENP1/2.

Minghua Nie, Michael N Boddy

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 31 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. The role of SUMOylation during development.Biochemical Society transactions · 2020
    Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Minghua NieFrom the Department of Cell and Molecular Biology, The Scripps Research Institute, La Jolla, California 92037.
Michael N BoddyFrom the Department of Cell and Molecular Biology, The Scripps Research Institute, La Jolla, California 92037 nboddy@scripps.edu.
Scripps Research Institute · US

Funding

Studies of the Rad60-Smc5-Smc6 DNA Repair ComplexR01GM068608 · NIGMS · SCRIPPS RESEARCH INSTITUTE, THE · PI BODDY, MICHAEL N · 2003 to 2020
$6.2M
SUMO-dependent Regulation of Ubiquitin Ligases in Genomic StabilityR01GM081840 · NIGMS · SCRIPPS RESEARCH INSTITUTE, THE · PI BODDY, MICHAEL N · 2009 to 2018
$3.0M
NIGMS NIH HHS GM068608NIGMS NIH HHS GM081840NIGMS NIH HHS R01 GM068608NIGMS NIH HHS R01 GM081840
6 · The paper itself

Abstract

Covalent modification of the proteome by SUMO is critical for genetic stability and cell growth. Equally crucial to these processes is the removal of SUMO from its targets by the Ulp1 (HuSENP1/2) family of SUMO proteases. Ulp1 activity is normally spatially restricted, because it is localized to the nuclear periphery via interactions with the nuclear pore. Delocalization of Ulp1 causes DNA damage and cell cycle defects, phenotypes thought to be caused by inappropriate desumoylation of nucleoplasmic targets that are normally spatially protected from Ulp1. Here, we define a novel consequence of Ulp1 deregulation, with a major impact on SUMO pathway function. In fission yeast lacking Nup132 (Sc/HuNUP133), Ulp1 is delocalized and can no longer antagonize sumoylation of the PIAS family SUMO E3 ligase, Pli1. Consequently, SUMO chain-modified Pli1 is targeted for proteasomal degradation by the concerted action of a SUMO-targeted ubiquitin ligase (STUbL) and Cdc48-Ufd1-Npl4. Pli1 degradation causes the profound SUMO pathway defects and associated centromere dysfunction in cells lacking Nup132. Thus, perhaps counterintuitively, Ulp1-mediated desumoylation can promote SUMO modification by stabilizing a SUMO E3 ligase.

Indexed as

Cysteine EndopeptidasesEndopeptidasesHumansProtein Inhibitors of Activated STATSchizosaccharomycesSchizosaccharomyces pombe ProteinsSmall Ubiquitin-Related Modifier ProteinsSUMO-1 ProteinSumoylationUbiquitin-Protein LigasesCysteine EndopeptidasesEndopeptidasesPIAS1 protein, humanProtein Inhibitors of Activated STATSchizosaccharomyces pombe ProteinsSENP1 protein, humanSENP2 protein, humanSmall Ubiquitin-Related Modifier ProteinsSUMO-1 ProteinUbiquitin-Protein LigasesUlp1 proteaseCdc48-Ufd1-Npl4nuclear porePli1proteasomeprotein degradationsmall ubiquitin-like modifier (SUMO)STUbLsumoylationUlp1

Identifiers

PMID26221037
PMCPMC4566240
OpenAlexW973140831

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.